StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns

Completed · Phase 1

Conditions studied: Skin Wound, Burns, Trauma-related Wound

In brief

The proposed study is designed as a phase Ib open-label, dose-escalation, multicenter study evaluating the safety, tolerability, and efficacy of StrataGraft skin tissue in promoting the healing of the deep partial-thickness component of complex skin defects. The proposed study population will include patients with 3-49% Total Body Surface Area (TBSA) complex skin defects including a deep partial-thickness component resulting from thermal injury. The study has been designed to focus on the evaluation of safety and tolerability of prolonged exposure to increasing amounts of a single application of StrataGraft skin tissue, while also assessing the potential for StrataGraft tissue to promote healing of the deep partial-thickness component of these complex skin defects as an alternative to donor site harvesting and autografting. Targeted enrollment for this study is up to 30 patients with complex skin defects due to thermal burns which require surgical excision and autografting. Subjects will be sequentially enrolled in two cohorts of increasing treatment area receiving StrataGraft skin tissue that has been stored refrigerated prior to clinical use. A third cohort will receive StrataGraft skin tissue which has been stored cryopreserved and thawed in the operating room just prior to grafting.

Key facts

Study ID

NCT01437852

Run by

Stratatech, a Mallinckrodt Company

People needed

30

Starts

2011-09-01

Expected to finish

2014-10-01

Last updated by the study team

2019-10-16

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women aged 18-65 years, inclusive
• Written informed consent
• Sufficient healthy skin identified and designated as a donor site in the event that the StrataGraft treatment site requires autografting
• Complex skin defects of 3-49% TBSA requiring excision and autografting
• Total burn may consist of more than one wound area
• Deep partial-thickness thermal burn(s) with total area of 88 to 880 cm2 requiring excision and autografting
• First excision and grafting of treatment sites

You may not qualify if…

• Pregnant women and prisoners
• Patients receiving systemic immunosuppressive therapy
• Patients with a known history of malignancy
• Preadmission insulin-dependent diabetic patients
• Patients with concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives
• Expected survival of less than three months
• Participation in the treatment group of an interventional study within preceding 90 days prior to enrollment
• Full-thickness burns will be excluded as treatment sites
• Chronic wounds will be excluded as treatment sites
• The face, head, neck, hands, feet, buttocks, and areas over joints will be excluded as treatment sites
• Treatment sites adjacent to unexcised eschar
• Clinical suspicion of burn wound infection at the anticipated treatment sites

Where it is running

• Maricopa Integrated Health Systems, Arizona Burn Center — Phoenix, Arizona, United States
• University of Colorado Hospital Burn Center — Aurora, Colorado, United States
• Wake Forest University Baptist Medical Center — Winston-Salem, North Carolina, United States
• UT-Southwestern Medical Center — Dallas, Texas, United States
• U.S. Army Institute of Surgical Research — Fort Sam Houston, Texas, United States
• University of Wisconsin Hospital — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.